{"id":4252,"date":"2026-09-05T17:03:18","date_gmt":"2026-09-05T14:03:18","guid":{"rendered":"https:\/\/wniss.com\/?p=4252"},"modified":"2026-09-05T17:04:10","modified_gmt":"2026-09-05T14:04:10","slug":"reviewing-clinical-advances-in-new-drugs-for-depression","status":"publish","type":"post","link":"https:\/\/wniss.com\/en-gb\/reviewing-clinical-advances-in-new-drugs-for-depression\/","title":{"rendered":"Reviewing Clinical Advances in New Drugs for Depression"},"content":{"rendered":"<figure class=\"wch-inserted-image\"><img decoding=\"async\" width=\"1024\" height=\"683\" src=\"https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-new-drugs-for-depression-1-RZCyPQ-1024x683.webp\" alt=\"Reviewing Clinical Advances in New Drugs for Depression - Reviewing Clinical Advances in New\" loading=\"lazy\" class=\"wp-image-6095\" title=\"\" srcset=\"https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-new-drugs-for-depression-1-RZCyPQ-1024x683.webp 1024w, https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-new-drugs-for-depression-1-RZCyPQ-300x200.webp 300w, https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-new-drugs-for-depression-1-RZCyPQ-150x100.webp 150w, https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-new-drugs-for-depression-1-RZCyPQ-100x67.webp 100w, https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-new-drugs-for-depression-1-RZCyPQ-200x133.webp 200w, https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-new-drugs-for-depression-1-RZCyPQ-250x167.webp 250w, https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-new-drugs-for-depression-1-RZCyPQ-350x233.webp 350w, https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-new-drugs-for-depression-1-RZCyPQ-400x267.webp 400w, https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-new-drugs-for-depression-1-RZCyPQ-500x333.webp 500w, https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-new-drugs-for-depression-1-RZCyPQ-600x400.webp 600w, https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-new-drugs-for-depression-1-RZCyPQ.webp 1200w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n<div class=\"markdown prose dark:prose-invert wrap-break-word w-full light markdown-new-styling\"><h2><span class=\"ez-toc-section\" id=\"Reviewing_Clinical_Advances_in_New_Drugs_for_Depression\"><\/span>Reviewing Clinical Advances in New Drugs for Depression<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>BLUF (Bottom Line Up Front):<\/strong><br>\nNew drugs for depression are changing treatment beyond traditional serotonin-based antidepressants. Recent advances focus on faster symptom relief, treatment-resistant depression, postpartum depression, glutamate pathways, GABA systems, and personalized medicine approaches. Although promising, many newer therapies still require careful medical evaluation because long-term safety, accessibility, and optimal treatment sequencing remain active research areas. <span class=\"\"><span class=\"ms-1 inline-flex max-w-full items-center select-none relative top-[-0.094rem] translate-y-0.5 animate-[show_150ms_ease-in]\" style=\"width: 116px;\"><span class=\"flex h-4.5 overflow-hidden rounded-xl pe-2 ps-1 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! select-none\"><span class=\"relative start-0 bottom-0 flex h-full w-full items-center\"><span class=\"flex h-4 w-full items-center justify-between\" style=\"opacity: 1; transform: none;\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">PubMed<\/span><\/span><span class=\"-me-1 flex h-full items-center rounded-full px-1 text-[#8F8F8F]\">+1<\/span><\/span><\/span><\/span><\/span><\/span><\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_88 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-clinical-advances-in-new-drugs-for-depression\/#Reviewing_Clinical_Advances_in_New_Drugs_for_Depression\" >Reviewing Clinical Advances in New Drugs for Depression<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-clinical-advances-in-new-drugs-for-depression\/#How_New_Drugs_for_Depression_Differ_From_Traditional_Antidepressants\" >How New Drugs for Depression Differ From Traditional Antidepressants<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-clinical-advances-in-new-drugs-for-depression\/#Advances_in_Rapid-Acting_Antidepressant_Medications\" >Advances in Rapid-Acting Antidepressant Medications<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-clinical-advances-in-new-drugs-for-depression\/#Esketamine_and_the_Glutamate_Pathway\" >Esketamine and the Glutamate Pathway<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-clinical-advances-in-new-drugs-for-depression\/#Dextromethorphan-Bupropion_Combination_Therapy\" >Dextromethorphan-Bupropion Combination Therapy<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-clinical-advances-in-new-drugs-for-depression\/#New_Medication_Options_for_Postpartum_Depression\" >New Medication Options for Postpartum Depression<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-clinical-advances-in-new-drugs-for-depression\/#Zuranolone_and_Short-Course_Treatment\" >Zuranolone and Short-Course Treatment<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-clinical-advances-in-new-drugs-for-depression\/#Psychedelic-Based_Depression_Treatments_Under_Investigation\" >Psychedelic-Based Depression Treatments Under Investigation<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-clinical-advances-in-new-drugs-for-depression\/#Psilocybin_Research\" >Psilocybin Research<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-clinical-advances-in-new-drugs-for-depression\/#Personalized_Medicine_and_the_Future_of_Depression_Drugs\" >Personalized Medicine and the Future of Depression Drugs<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-clinical-advances-in-new-drugs-for-depression\/#Moving_Beyond_Trial-and-Error_Prescribing\" >Moving Beyond Trial-and-Error Prescribing<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-clinical-advances-in-new-drugs-for-depression\/#Biomarker-Based_Treatments\" >Biomarker-Based Treatments<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-clinical-advances-in-new-drugs-for-depression\/#Emerging_Drug_Targets_Beyond_Serotonin\" >Emerging Drug Targets Beyond Serotonin<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-clinical-advances-in-new-drugs-for-depression\/#NMDA_Receptor_Treatments\" >NMDA Receptor Treatments<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-clinical-advances-in-new-drugs-for-depression\/#GABA_System_Modulation\" >GABA System Modulation<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-clinical-advances-in-new-drugs-for-depression\/#Inflammation_and_Immune-Based_Treatments\" >Inflammation and Immune-Based Treatments<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-clinical-advances-in-new-drugs-for-depression\/#Challenges_Facing_New_Depression_Medications\" >Challenges Facing New Depression Medications<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-clinical-advances-in-new-drugs-for-depression\/#Long-Term_Safety_Evidence\" >Long-Term Safety Evidence<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-clinical-advances-in-new-drugs-for-depression\/#Cost_and_Accessibility\" >Cost and Accessibility<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-clinical-advances-in-new-drugs-for-depression\/#Correct_Patient_Selection\" >Correct Patient Selection<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-clinical-advances-in-new-drugs-for-depression\/#Comparing_Traditional_and_New_Depression_Treatments\" >Comparing Traditional and New Depression Treatments<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-clinical-advances-in-new-drugs-for-depression\/#The_Role_of_Doctors_in_Choosing_New_Depression_Drugs\" >The Role of Doctors in Choosing New Depression Drugs<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-clinical-advances-in-new-drugs-for-depression\/#Future_Directions_in_Depression_Pharmacology\" >Future Directions in Depression Pharmacology<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-clinical-advances-in-new-drugs-for-depression\/#Frequently_Asked_Questions_FAQs\" >Frequently Asked Questions (FAQs)<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-clinical-advances-in-new-drugs-for-depression\/#1_What_are_the_newest_drugs_being_studied_for_depression\" >1. What are the newest drugs being studied for depression?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-clinical-advances-in-new-drugs-for-depression\/#2_Do_new_antidepressants_work_faster_than_older_medications\" >2. Do new antidepressants work faster than older medications?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-clinical-advances-in-new-drugs-for-depression\/#3_Are_new_depression_drugs_safer_than_traditional_antidepressants\" >3. Are new depression drugs safer than traditional antidepressants?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-28\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-clinical-advances-in-new-drugs-for-depression\/#4_Can_new_drugs_treat_treatment-resistant_depression\" >4. Can new drugs treat treatment-resistant depression?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-29\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-clinical-advances-in-new-drugs-for-depression\/#5_Will_future_depression_treatment_become_personalized\" >5. Will future depression treatment become personalized?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-30\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-clinical-advances-in-new-drugs-for-depression\/#Medical_Disclaimer\" >Medical Disclaimer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-31\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-clinical-advances-in-new-drugs-for-depression\/#Source_Reference\" >Source Reference<\/a><\/li><\/ul><\/nav><\/div>\n\n<div class=\"TyagGW_tableContainer\"><div tabindex=\"-1\" class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\"><table class=\"w-fit min-w-(--thread-content-width)\"><thead><tr><th class=\"last:pe-10\">Treatment advance<\/th><th class=\"last:pe-10\">Main target<\/th><th class=\"last:pe-10\">Current role<\/th><th class=\"last:pe-10\">Key clinical advantage<\/th><\/tr><\/thead><tbody><tr><td>Esketamine nasal therapy<\/td><td>NMDA\/glutamate pathway<\/td><td>Treatment-resistant depression<\/td><td>Rapid antidepressant effects<\/td><\/tr><tr><td>Dextromethorphan-bupropion combination<\/td><td>NMDA and monoamine pathways<\/td><td>Major depressive disorder<\/td><td>Oral option with faster action potential<\/td><\/tr><tr><td>Zuranolone<\/td><td>GABA-A receptors<\/td><td>Postpartum depression<\/td><td>Short-course treatment approach<\/td><\/tr><tr><td>Psychedelic-based medicines<\/td><td>Serotonin 2A receptors<\/td><td>Investigational depression treatment<\/td><td>Potential rapid and durable response<\/td><\/tr><tr><td>Personalized treatments<\/td><td>Biomarkers, genetics, brain stimulation integration<\/td><td>Emerging field<\/td><td>More individualized medication selection<\/td><\/tr><\/tbody><\/table><div class=\"relative h-0 self-end select-none\"><div class=\"absolute end-0 flex items-end\" style=\"height: 65px;\"><span class=\"\"><button aria-label=\"\u0646\u0633\u062e \u0627\u0644\u062c\u062f\u0648\u0644\" class=\"hover:bg-token-bg-tertiary text-token-text-secondary relative z-10 my-1 rounded-sm p-1 transition-opacity group-[:not(:hover):not(:focus-within)]:pointer-events-none group-[:not(:hover):not(:focus-within)]:opacity-0\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"20\" height=\"20\" aria-hidden=\"true\" class=\"icon\"><use href=\"\/cdn\/assets\/sprites-core-18ad762e.svg#ce3544\" fill=\"currentColor\"><\/use><\/svg><\/button><\/span><\/div><\/div><\/div><\/div>\n<h2><span class=\"ez-toc-section\" id=\"How_New_Drugs_for_Depression_Differ_From_Traditional_Antidepressants\"><\/span>How New Drugs for Depression Differ From Traditional Antidepressants<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>For decades, most antidepressants were designed around increasing serotonin, norepinephrine, or dopamine activity. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) remain widely used because of their established effectiveness and safety profiles.<\/p>\n<p>However, researchers have identified limitations with conventional treatments. Many patients experience delayed improvement, incomplete symptom relief, or treatment-resistant depression despite receiving appropriate care. Recent clinical development has therefore shifted toward medications that influence different biological pathways. <span class=\"\"><span class=\"ms-1 inline-flex max-w-full items-center select-none relative top-[-0.094rem] translate-y-0.5 animate-[show_150ms_ease-in]\" style=\"width: 101px;\"><span class=\"flex h-4.5 overflow-hidden rounded-xl pe-2 ps-1 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! select-none\"><span class=\"relative start-0 bottom-0 flex h-full w-full items-center\"><span class=\"flex h-4 w-full items-center justify-between overflow-hidden\" style=\"opacity: 1; transform: none;\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">PMC<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n<p>New drugs for depression increasingly explore:<\/p>\n<ul>\n<li>\n<p>Glutamate regulation through NMDA receptors.<\/p>\n<\/li>\n<li>\n<p>GABA-related brain signaling.<\/p>\n<\/li>\n<li>\n<p>Neuroplasticity enhancement.<\/p>\n<\/li>\n<li>\n<p>Hormonal and immune pathways.<\/p>\n<\/li>\n<li>\n<p>Biomarker-guided treatment selection.<\/p>\n<\/li>\n<\/ul>\n<p>These approaches aim to provide faster, more targeted, and more personalized depression care.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Advances_in_Rapid-Acting_Antidepressant_Medications\"><\/span>Advances in Rapid-Acting Antidepressant Medications<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Esketamine_and_the_Glutamate_Pathway\"><\/span>Esketamine and the Glutamate Pathway<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>One of the most important advances in depression treatment has been the development of ketamine-related therapies. Esketamine, delivered as a nasal spray, works mainly through NMDA receptor modulation within the glutamate system.<\/p>\n<p>Unlike traditional antidepressants that often require several weeks for noticeable benefits, glutamate-based treatments may produce improvements more rapidly in some individuals with treatment-resistant depression. Clinical reviews identify intranasal esketamine as one of the major modern advances in antidepressant pharmacotherapy. <span class=\"\"><span class=\"ms-1 inline-flex max-w-full items-center select-none relative top-[-0.094rem] translate-y-0.5 animate-[show_150ms_ease-in]\" style=\"width: 62px;\"><span class=\"flex h-4.5 overflow-hidden rounded-xl pe-2 ps-1 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! select-none\"><span class=\"relative start-0 bottom-0 flex h-full w-full items-center\"><span class=\"flex h-4 w-full items-center justify-between overflow-hidden\" style=\"opacity: 1; transform: none;\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">PubMed<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n<p>However, esketamine requires medical supervision because clinicians must monitor possible side effects, including dissociation, blood pressure changes, and misuse risks.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Dextromethorphan-Bupropion_Combination_Therapy\"><\/span>Dextromethorphan-Bupropion Combination Therapy<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Another newer oral approach combines dextromethorphan with bupropion. This medication strategy targets NMDA receptors while also affecting dopamine and norepinephrine pathways.<\/p>\n<p>Clinical research has explored this combination as an alternative for adults with major depressive disorder who may not respond adequately to standard antidepressants. Recent pharmacotherapy reviews highlight dextromethorphan-bupropion among newer treatments expanding beyond traditional monoamine mechanisms. <span class=\"\"><span class=\"ms-1 inline-flex max-w-full items-center select-none relative top-[-0.094rem] translate-y-0.5 animate-[show_150ms_ease-in]\" style=\"width: 62px;\"><span class=\"flex h-4.5 overflow-hidden rounded-xl pe-2 ps-1 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! select-none\"><span class=\"relative start-0 bottom-0 flex h-full w-full items-center\"><span class=\"flex h-4 w-full items-center justify-between overflow-hidden\" style=\"opacity: 1; transform: none;\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">PubMed<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n<h2><span class=\"ez-toc-section\" id=\"New_Medication_Options_for_Postpartum_Depression\"><\/span>New Medication Options for Postpartum Depression<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Zuranolone_and_Short-Course_Treatment\"><\/span>Zuranolone and Short-Course Treatment<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Postpartum depression has received increased attention because symptoms can significantly affect both the mother and infant. Zuranolone represents a newer medication approach targeting GABA-A receptor activity.<\/p>\n<p>Unlike many antidepressants that are taken continuously for months, zuranolone was developed as a shorter treatment course. This approach may provide a different option for eligible patients under medical supervision.<\/p>\n<p>Clinical reviews identify postpartum depression treatments as an important area of recent antidepressant development because hormonal changes and neurological adaptations create unique therapeutic challenges. <span class=\"\"><span class=\"ms-1 inline-flex max-w-full items-center select-none relative top-[-0.094rem] translate-y-0.5 animate-[show_150ms_ease-in]\" style=\"width: 62px;\"><span class=\"flex h-4.5 overflow-hidden rounded-xl pe-2 ps-1 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! select-none\"><span class=\"relative start-0 bottom-0 flex h-full w-full items-center\"><span class=\"flex h-4 w-full items-center justify-between overflow-hidden\" style=\"opacity: 1; transform: none;\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">PubMed<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Psychedelic-Based_Depression_Treatments_Under_Investigation\"><\/span>Psychedelic-Based Depression Treatments Under Investigation<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Psilocybin_Research\"><\/span>Psilocybin Research<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Psychedelic compounds, particularly psilocybin, are being studied as possible treatments for major depressive disorder and treatment-resistant depression.<\/p>\n<p>Researchers are investigating whether controlled psychedelic-assisted therapy can produce meaningful improvements through serotonin 2A receptor activity and changes in neural flexibility. Recent regulatory activity has accelerated research interest in psychedelic medicines for serious mental health conditions, including depression. <span class=\"\"><span class=\"ms-1 inline-flex max-w-full items-center select-none relative top-[-0.094rem] translate-y-0.5 animate-[show_150ms_ease-in]\" style=\"width: 58px;\"><span class=\"flex h-4.5 overflow-hidden rounded-xl pe-2 ps-1 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! select-none\"><span class=\"relative start-0 bottom-0 flex h-full w-full items-center\"><span class=\"flex h-4 w-full items-center justify-between overflow-hidden\" style=\"opacity: 1; transform: none;\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">U.S. Food and Drug Administration<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n<p>Despite promising findings, important questions remain:<\/p>\n<ul>\n<li>\n<p>How long benefits last after treatment.<\/p>\n<\/li>\n<li>\n<p>Which patients are most likely to respond.<\/p>\n<\/li>\n<li>\n<p>How therapy should be integrated safely.<\/p>\n<\/li>\n<li>\n<p>How risks should be managed.<\/p>\n<\/li>\n<\/ul>\n<p>These medications remain highly dependent on clinical trial evidence and regulatory approval processes.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Personalized_Medicine_and_the_Future_of_Depression_Drugs\"><\/span>Personalized Medicine and the Future of Depression Drugs<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Moving_Beyond_Trial-and-Error_Prescribing\"><\/span>Moving Beyond Trial-and-Error Prescribing<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>A major challenge in depression care is predicting which medication will work best for each person. Traditionally, physicians often use a step-by-step approach: selecting a medication, monitoring response, and adjusting treatment when necessary.<\/p>\n<p>Future approaches aim to improve this process using:<\/p>\n<ul>\n<li>\n<p>Genetic information.<\/p>\n<\/li>\n<li>\n<p>Brain imaging.<\/p>\n<\/li>\n<li>\n<p>Blood biomarkers.<\/p>\n<\/li>\n<li>\n<p>Digital health monitoring.<\/p>\n<\/li>\n<li>\n<p>Artificial intelligence prediction models.<\/p>\n<\/li>\n<\/ul>\n<p>Research into personalized depression treatment suggests that future systems may help clinicians identify patients who are more likely to benefit from specific therapies. <span class=\"\"><span class=\"ms-1 inline-flex max-w-full items-center select-none relative top-[-0.094rem] translate-y-0.5 animate-[show_150ms_ease-in]\" style=\"width: 62px;\"><span class=\"flex h-4.5 overflow-hidden rounded-xl pe-2 ps-1 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! select-none\"><span class=\"relative start-0 bottom-0 flex h-full w-full items-center\"><span class=\"flex h-4 w-full items-center justify-between overflow-hidden\" style=\"opacity: 1; transform: none;\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">PubMed<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n<h3><span class=\"ez-toc-section\" id=\"Biomarker-Based_Treatments\"><\/span>Biomarker-Based Treatments<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Scientists are also exploring biological subtypes of depression. Instead of viewing depression as one condition, researchers are investigating whether different biological patterns require different treatments.<\/p>\n<p>Examples include:<\/p>\n<ul>\n<li>\n<p>Inflammation-related depression.<\/p>\n<\/li>\n<li>\n<p>Glutamate-related depression.<\/p>\n<\/li>\n<li>\n<p>Hormonal depression patterns.<\/p>\n<\/li>\n<li>\n<p>Cognitive symptom-focused depression.<\/p>\n<\/li>\n<\/ul>\n<p>This could eventually replace generalized medication selection with more individualized treatment plans.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Emerging_Drug_Targets_Beyond_Serotonin\"><\/span>Emerging Drug Targets Beyond Serotonin<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"NMDA_Receptor_Treatments\"><\/span>NMDA Receptor Treatments<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>NMDA-targeting medications represent one of the most significant changes in antidepressant research. These treatments focus on glutamate, the brain\u2019s primary excitatory neurotransmitter.<\/p>\n<p>Potential benefits include:<\/p>\n<ul>\n<li>\n<p>Faster symptom improvement.<\/p>\n<\/li>\n<li>\n<p>Effects on severe depressive symptoms.<\/p>\n<\/li>\n<li>\n<p>New possibilities for treatment-resistant cases.<\/p>\n<\/li>\n<\/ul>\n<h3><span class=\"ez-toc-section\" id=\"GABA_System_Modulation\"><\/span>GABA System Modulation<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>GABA-based medications are another expanding research area. Since GABA influences emotional regulation and stress responses, scientists are investigating whether modifying this pathway can improve depressive symptoms.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Inflammation_and_Immune-Based_Treatments\"><\/span>Inflammation and Immune-Based Treatments<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Researchers are also examining connections between immune activity and depression. Some studies suggest that certain patients may have inflammatory patterns linked to depressive symptoms, creating interest in immune-targeted therapies. <span class=\"\"><span class=\"ms-1 inline-flex max-w-full items-center select-none relative top-[-0.094rem] translate-y-0.5 animate-[show_150ms_ease-in]\" style=\"width: 90px;\"><span class=\"flex h-4.5 overflow-hidden rounded-xl pe-2 ps-1 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! select-none\"><span class=\"relative start-0 bottom-0 flex h-full w-full items-center\"><span class=\"flex h-4 w-full items-center justify-between overflow-hidden\" style=\"opacity: 1; transform: none;\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">Live Science<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Challenges_Facing_New_Depression_Medications\"><\/span>Challenges Facing New Depression Medications<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Although new treatments offer hope, several challenges remain.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Long-Term_Safety_Evidence\"><\/span>Long-Term Safety Evidence<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Many newer medications have shorter clinical histories compared with traditional antidepressants. Researchers continue evaluating:<\/p>\n<ul>\n<li>\n<p>Long-term effectiveness.<\/p>\n<\/li>\n<li>\n<p>Withdrawal effects.<\/p>\n<\/li>\n<li>\n<p>Relapse prevention.<\/p>\n<\/li>\n<li>\n<p>Rare adverse reactions.<\/p>\n<\/li>\n<\/ul>\n<h3><span class=\"ez-toc-section\" id=\"Cost_and_Accessibility\"><\/span>Cost and Accessibility<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Advanced treatments may be expensive or require specialized clinics. Limited availability can prevent some patients from accessing newer options.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Correct_Patient_Selection\"><\/span>Correct Patient Selection<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>A medication that works well for one person may not benefit another. Accurate diagnosis, medical history review, and ongoing monitoring remain essential.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Comparing_Traditional_and_New_Depression_Treatments\"><\/span>Comparing Traditional and New Depression Treatments<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div class=\"TyagGW_tableContainer\"><div tabindex=\"-1\" class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\"><table class=\"w-fit min-w-(--thread-content-width)\"><thead><tr><th class=\"last:pe-10\">Category<\/th><th class=\"last:pe-10\">Traditional antidepressants<\/th><th class=\"last:pe-10\">Newer depression medications<\/th><\/tr><\/thead><tbody><tr><td>Main mechanisms<\/td><td>Serotonin and norepinephrine systems<\/td><td>Glutamate, GABA, serotonin receptors, biomarkers<\/td><\/tr><tr><td>Speed of action<\/td><td>Usually weeks<\/td><td>Some may act faster<\/td><\/tr><tr><td>Experience level<\/td><td>Decades of evidence<\/td><td>Growing evidence base<\/td><\/tr><tr><td>Common use<\/td><td>First-line depression treatment<\/td><td>Treatment-resistant or specialized cases<\/td><\/tr><tr><td>Personalization<\/td><td>Limited prediction ability<\/td><td>Increasing biomarker focus<\/td><\/tr><\/tbody><\/table><div class=\"relative h-0 self-end select-none\"><div class=\"absolute end-0 flex items-end\" style=\"height: 49px;\"><span class=\"\"><button aria-label=\"\u0646\u0633\u062e \u0627\u0644\u062c\u062f\u0648\u0644\" class=\"hover:bg-token-bg-tertiary text-token-text-secondary relative z-10 my-1 rounded-sm p-1 transition-opacity group-[:not(:hover):not(:focus-within)]:pointer-events-none group-[:not(:hover):not(:focus-within)]:opacity-0\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"20\" height=\"20\" aria-hidden=\"true\" class=\"icon\"><use href=\"\/cdn\/assets\/sprites-core-18ad762e.svg#ce3544\" fill=\"currentColor\"><\/use><\/svg><\/button><\/span><\/div><\/div><\/div><\/div>\n<h2><span class=\"ez-toc-section\" id=\"The_Role_of_Doctors_in_Choosing_New_Depression_Drugs\"><\/span>The Role of Doctors in Choosing New Depression Drugs<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Medication selection should always consider:<\/p>\n<ul>\n<li>\n<p>Depression severity.<\/p>\n<\/li>\n<li>\n<p>Previous treatment response.<\/p>\n<\/li>\n<li>\n<p>Other medical conditions.<\/p>\n<\/li>\n<li>\n<p>Current medications.<\/p>\n<\/li>\n<li>\n<p>Suicide risk assessment.<\/p>\n<\/li>\n<li>\n<p>Personal treatment goals.<\/p>\n<\/li>\n<\/ul>\n<p>New drugs for depression are not automatically better than established treatments. Instead, they expand the range of options available when standard approaches are insufficient.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Future_Directions_in_Depression_Pharmacology\"><\/span>Future Directions in Depression Pharmacology<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The future of depression treatment is moving toward:<\/p>\n<ul>\n<li>\n<p>Faster-acting medications.<\/p>\n<\/li>\n<li>\n<p>Individualized drug selection.<\/p>\n<\/li>\n<li>\n<p>Combination approaches.<\/p>\n<\/li>\n<li>\n<p>Integration with psychotherapy.<\/p>\n<\/li>\n<li>\n<p>Digital monitoring tools.<\/p>\n<\/li>\n<\/ul>\n<p>Researchers are also investigating whether combining medications with cognitive behavioral therapy, neuromodulation, and lifestyle interventions can improve long-term outcomes.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_FAQs\"><\/span>Frequently Asked Questions (FAQs)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"1_What_are_the_newest_drugs_being_studied_for_depression\"><\/span>1. What are the newest drugs being studied for depression?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>New research focuses on medications affecting glutamate, GABA, serotonin receptors, and personalized biological pathways. Examples include esketamine-related treatments, dextromethorphan-bupropion combinations, zuranolone, and psychedelic-based therapies under investigation. <span class=\"\"><span class=\"ms-1 inline-flex max-w-full items-center select-none relative top-[-0.094rem] translate-y-0.5 animate-[show_150ms_ease-in]\" style=\"width: 77px;\"><span class=\"flex h-4.5 overflow-hidden rounded-xl pe-2 ps-1 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! select-none\"><span class=\"relative start-0 bottom-0 flex h-full w-full items-center\"><span class=\"flex h-4 w-full items-center justify-between\" style=\"opacity: 1; transform: none;\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">PubMed<\/span><\/span><span class=\"-me-1 flex h-full items-center rounded-full px-1 text-[#8F8F8F]\">+1<\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n<h3><span class=\"ez-toc-section\" id=\"2_Do_new_antidepressants_work_faster_than_older_medications\"><\/span>2. Do new antidepressants work faster than older medications?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Some newer treatments may produce faster improvements, particularly glutamate-based therapies. However, response varies widely between individuals, and medical monitoring remains necessary.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"3_Are_new_depression_drugs_safer_than_traditional_antidepressants\"><\/span>3. Are new depression drugs safer than traditional antidepressants?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>New medications may offer advantages for certain patients, but safety depends on the specific drug, health history, dosage, and supervision. Long-term research continues.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"4_Can_new_drugs_treat_treatment-resistant_depression\"><\/span>4. Can new drugs treat treatment-resistant depression?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Several newer approaches were specifically developed or studied for treatment-resistant depression, including esketamine and investigational rapid-acting treatments. <span class=\"\"><span class=\"ms-1 inline-flex max-w-full items-center select-none relative top-[-0.094rem] translate-y-0.5 animate-[show_150ms_ease-in]\" style=\"width: 62px;\"><span class=\"flex h-4.5 overflow-hidden rounded-xl pe-2 ps-1 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! select-none\"><span class=\"relative start-0 bottom-0 flex h-full w-full items-center\"><span class=\"flex h-4 w-full items-center justify-between overflow-hidden\" style=\"opacity: 1; transform: none;\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">PubMed<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n<h3><span class=\"ez-toc-section\" id=\"5_Will_future_depression_treatment_become_personalized\"><\/span>5. Will future depression treatment become personalized?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Many researchers believe personalized treatment using biomarkers, genetics, and artificial intelligence may improve medication selection, but these approaches are still developing.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Medical_Disclaimer\"><\/span>Medical Disclaimer<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The information provided in this article is for educational and informational purposes only. It does not replace consultation with a qualified physician or healthcare professional. Do not use this information to diagnose or treat any medical condition. Always consult a healthcare provider before starting a new medication or changing an existing treatment plan.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Source_Reference\"><\/span>Source Reference<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Source link: <span class=\"decorated-link\">https:\/\/en.wikipedia.org\/wiki\/Depression_(mood)<span aria-hidden=\"true\" class=\"ms-0.5 inline-block align-middle leading-none select-none\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"20\" height=\"20\" aria-hidden=\"true\" class=\"block h-[0.75em] w-[0.75em] stroke-current stroke-[0.75] select-none\"><use href=\"\/cdn\/assets\/sprites-core-18ad762e.svg#304883\" fill=\"currentColor\"><\/use><\/svg><\/span><\/span><\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Reviewing Clinical Advances in New Drugs for Depression BLUF (Bottom Line Up Front): New drugs for depression are changing treatment beyond traditional [&hellip;]<\/p>\n","protected":false},"author":11,"featured_media":6095,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[730],"tags":[],"class_list":["post-4252","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-depression"],"acf":[],"_links":{"self":[{"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/posts\/4252","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/comments?post=4252"}],"version-history":[{"count":2,"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/posts\/4252\/revisions"}],"predecessor-version":[{"id":6096,"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/posts\/4252\/revisions\/6096"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/media\/6095"}],"wp:attachment":[{"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/media?parent=4252"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/categories?post=4252"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/tags?post=4252"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}